glp-1 deficiency receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease GLP-1 therapy is becoming a

A tendency to worse course of multisystem inflammatory syndrome in children with obesity: MultiOrgan Inflammatory syndromes COVID-19 related study

It helps soften fine lines but can be irritating for some

It is important to recognize that the cardiovascular and renal benefits of GLP-1 medications typically outweigh the potential for retinopathy progression in appropriately selected patients, and discontinuing these medications due to unfounded concerns about vision may result in worse overall health outcomes

The first drug in this class based on Exendin-4 isolated from the gila monster, Byetta (shown above), was approved by the FDA in 2005

With the same VYVANSE dose, mean steady state exposure of dextroamphetamine was approximately 44% higher in pediatric patients ages 4 to 5 years compared to the pediatric patients ages 6 to 11 years